Stock ANGEN ANATOLIA TANI VE BIYOTEKNOLOJI ÜRÜNLERI AR-GE SANAYI TICARET
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret

Equities

ANGEN

TREANGN00028

Biotechnology & Medical Research

Market Closed - Borsa Istanbul
Other stock markets
 08:38:05 05/07/2024 pm IST 		5-day change 1st Jan Change
11.78 TRY +0.94% Intraday chart for Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret +0.60% -5.38%
14/06 Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
10/05 Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 3,212 4,741 2,739
Enterprise Value (EV) 1 2,701 4,330 2,403
P/E ratio 5.1 x 14.3 x -20 x
Yield - 2.76% -
Capitalization / Revenue 7.83 x 17.6 x 11.5 x
EV / Revenue 6.59 x 16.1 x 10.1 x
EV / EBITDA 8.48 x 27.5 x 161 x
EV / FCF 3,56,80,324 x -43,97,18,036 x 4,49,94,994 x
FCF Yield 0% -0% 0%
Price to Book 4.19 x 5.81 x 2.26 x
Nbr of stocks (in thousands) 2,20,000 2,20,000 2,20,000
Reference price 2 14.60 21.55 12.45
Announcement Date 03/03/22 10/03/23 10/05/24
1TRY in Million2TRY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 421.6 410.1 268.8 238.2
EBITDA 1 347.3 318.7 157.3 14.95
EBIT 1 342.3 308.9 136.4 -44.29
Operating Margin 81.2% 75.33% 50.73% -18.59%
Earnings before Tax (EBT) 1 359.7 462.3 340.3 -146.1
Net income 1 293.4 433.3 330.4 -136.7
Net margin 69.6% 105.66% 122.9% -57.37%
EPS 2 1.938 2.862 1.502 -0.6212
Free Cash Flow - 75.71 -9.847 53.41
FCF margin - 18.46% -3.66% 22.42%
FCF Conversion (EBITDA) - 23.76% - 357.23%
FCF Conversion (Net income) - 17.47% - -
Dividend per Share - - 0.5958 -
Announcement Date 03/03/22 03/03/22 10/03/23 10/05/24
1TRY in Million2TRY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 105 511 411 336
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - 75.7 -9.85 53.4
ROE (net income / shareholders' equity) - 76.3% 40.9% -10%
ROA (Net income/ Total Assets) - 30.8% 9.93% -1.84%
Assets 1 - 1,409 3,327 7,415
Book Value Per Share 2 2.050 3.490 3.710 5.510
Cash Flow per Share 2 0.8900 2.100 1.470 1.370
Capex 1 69.6 77.4 94.1 -
Capex / Sales 16.51% 18.88% 35.01% -
Announcement Date 03/03/22 03/03/22 10/03/23 10/05/24
1TRY in Million2TRY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
11.78 TRY
Average target price
15.4 TRY
Spread / Average Target
+30.73%
Consensus

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ANATOLIA TANI VE BIYOTEKNOLOJI ÜRÜNLERI AR-GE SANAYI TICARET Stock Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret
-5.38% 78.86M
MODERNA, INC. Stock Moderna, Inc.
+18.97% 44.44B
LONZA GROUP AG Stock Lonza Group AG
+41.98% 40.03B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.06% 37.68B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+31.15% 31.46B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.29B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.32% 26.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.05% 13.8B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.28% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.41% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ANGEN Stock
  4. Financials Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret